Metformin, besides exhibiting strong in vivo anti-inflammatory properties, increases mptp-induced damage to the nigrostriatal dopaminergic system

Toxicology and Applied Pharmacology

Volumn 298, Issue , 2016, Pages 19-30

  Ismaiel, Afrah A K ^a   Espinosa Oliva, Ana M ^a   Santiago, Martiniano ^a   García Quintanilla, Albert ^a   Oliva Martín, María J ^a   Herrera, Antonio J ^a   Venero, José L ^a   de Pablos, Rocío M ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Diabetes mellitus; Dopaminergic system; Metformin; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; METFORMIN; ANTIINFLAMMATORY AGENT; DOPAMINE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL VIABILITY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROGLIA; MOUSE; NERVE CELL LESION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; RAT; SUBSTANTIA NIGRA; ANIMAL; C57BL MOUSE; CELL CULTURE TECHNIQUE; CELL LINE; CHEMICALLY INDUCED; CORPUS STRIATUM; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; OXIDATIVE STRESS; PARKINSONISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CELL CULTURE TECHNIQUES; CELL LINE; CORPUS STRIATUM; DOPAMINE; DOPAMINERGIC NEURONS; IMMUNOHISTOCHEMISTRY; MALE; METFORMIN; MICE, INBRED C57BL; MICROGLIA; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA;

EID: 84960927086     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2016.03.004     Document Type: Article

References (79)

1. Abdullah R., Basak I., Patil K.S., Alves G., Larsen J.P., Møller S.G. Parkinson's disease and age: the obvious but largely unexplored link. Exp. Gerontol. 2015, 68:33-38.
2. Ashabi G., Khalaj L., Khodagholi F., Goudarzvand M., Sarkaki A. Pre-treatment with metformin activates Nrf2 antioxidant pathways and inhibits inflammatory responses through induction of AMPK after transient global cerebral ischemia. Metab. Brain Dis. 2015, 30:747-754.
3. Berry C., La Vecchia C., Nicotera P. Paraquat and Parkinson's disease. Cell Death Differ. 2010, 17:1115-1125.
4. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Crossman A.R., Bioulac B., Brotchie J.M., Gross C.E. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 2001, 21:6853-6861.
5. Blesa J., Przedborski S. Parkinson's disease: animal models and dopaminergic cell vulnerability. Front. Neuroanat. 2014, 8:8:155.
6. Brunmair B., Staniek K., Gras F., Scharf N., Althaym A., Clara R., Roden M., Gnaiger E., Nohl H., Waldhäusl W., Fürnsinn C. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?. Diabetes 2004, 53:1052-1059.
7. Chen H., Zhang S.M., Hernán M.A., Schwarzschild M.A., Willett W.C., Colditz G.A., Speizer F.E., Ascherio A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 2003, 60:1059-1064.
8. Chen H., Jacobs E., Schwarzschild M.A., McCullough M.L., Calle E.E., Thun M.J., Ascherio A. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann. Neurol. 2005, 58:963-967.
9. Chen L., Shu Y., Liang X., Chen E.C., Yee S.W., Zur A.A., Li S., Xu L., Keshari K.R., Lin M.J., Chien H.C., Zhang Y., Morrissey K.M., Liu J., Ostrem J., Younger N.S., Kurhanewicz J., Shokat K.M., Ashrafi K., Giacomini K.M. OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:9983-9988.
10. Chen S.H., Oyarzabal E.A., Hong J.S. Critical role of the Mac1/NOX2 pathway in mediating reactive microgliosis-generated chronic neuroinflammation and progressive neurodegeneration. Curr. Opin. Pharmacol. 2015, 26:54-60.
11. Chiba K., Peterson L.A., Castagnoli K.P., Trevor A.J., Castagnoli N. Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Drug Metab. Dispos. 1985, 13:342-347.
12. Christensen M.M., Højlund K., Hother-Nielsen O., Stage T.B., Damkier P., Beck-Nielsen H., Brøsen K. Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. Eur. J. Clin. Pharmacol. 2015, 71:691-697.
13. Cicchetti F., Brownell A.L., Williams K., Chen Y.I., Livni E., Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur. J. Neurosci. 2002, 15:991-998.
14. Clarkson E.D., Rosa F.G., Edwards-Prasad J., Weiland D.A., Witta S.E., Freed C.R., Prasad K.N. Improvement of neurological deficits in 6-hydroxydopamine-lesioned rats after transplantation with allogeneic simian virus 40 large tumor antigen gene-induced immortalized dopamine cells. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:1265-1270.
15. Cochemé H.M., Murphy M.P. Complex I is the major site of mitochondrial superoxide production by paraquat. J. Biol. Chem. 2008, 283:1786-1798.
16. Craft S., Watson G.S. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004, 3:169-178.
17. Cui M., Aras R., Christian W.V., Rappold P.M., Hatwar M., Panza J., Jackson-Lewis V., Javitch J.A., Ballatori N., Przedborski S., Tieu K. The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:8043-8048.
18. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
19. Detaille D., Guigas B., Chauvin C., Batandier C., Fontaine E., Wiernsperger N., Leverve X. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 2005, 54:2179-2187.
20. Di Monte D.A., Langston J.W. Idiopathic and 1-Methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism 1995, 981-982. Neuroglia Oxford University Press, Oxford. H. Kettenmann, B.R. Ransom (Eds.).
21. El-Mir M.Y., Nogueira V., Fontaine E., Avéret N., Rigoulet M., Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 2000, 275:223-228.
22. El-Mir M.Y., Detaille D., R-Villanueva G., Delgado-Esteban M., Guigas B., Attia S., Fontaine E., Almeida A., Leverve X. Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. J. Mol. Neurosci. 2008, 34:77-87.
23. Esposito E., Di Matteo V., Benigno A., Pierucci M., Crescimanno G., Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp. Neurol. 2007, 205:295-312.
24. Gao H.M., Liu B., Zhang W., Hong J.S. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol. Sci. 2003, 24:395-401.
25. Gao H.M., Liu B., Zhang W., Hong J.S. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. FASEB J. 2003, 17:1957-1959.
26. Giri S., Nath N., Smith B., Viollet B., Singh A.K., Singh I. 5-Aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J. Neurosci. 2004, 24:479-487.
27. Gundersen H.J., Bagger P., Bendtsen T.F., Evans S.M., Korbo L., Marcussen N., Møller A., Nielsen K., Nyengaard J.R., Pakkenberg B. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 1988, 96:857-881.
28. Hawley S.A., Boudeau J., Reid J.L., Mustard K.J., Udd L., Mäkelä T.P., Alessi D.R., Hardie D.G. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2003, 2:28.
29. Hawley S.A., Pan D.A., Mustard K.J., Ross L., Bain J., Edelman A.M., Frenguelli B.G., Hardie D.G. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2005, 2:9-19.
30. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 1984, 224:1451-1453.
31. Hinke S.A., Martens G.A., Cai Y., Finsi J., Heimberg H., Pipeleers D., Van de Casteele M. Methyl succinate antagonises biguanide-induced AMPK-activation and death of pancreatic beta-cells through restoration of mitochondrial electron transfer. Br. J. Pharmacol. 2007, 150:1031-1043.
32. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009, 8:382-397.
33. Hirsch E.C., Vyas S., Hunot S. Neuroinflammation in Parkinson's disease. Parkinsonism Relat. Disord. 2012, 18(Suppl. 1):S210-S212.
34. Horan M.P. Application of serial analysis of gene expression to the study of human genetic disease. Hum. Genet. 2009, 126:605-614.
35. Hunot S., Hirsch E.C. Neuroinflammatory processes in Parkinson's disease. Ann. Neurol. 2003, 53(Suppl. 3):S49-S58. (discussion S58-60).
36. Isoda K., Young J.L., Zirlik A., MacFarlane L.A., Tsuboi N., Gerdes N., Schönbeck U., Libby P. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler. Thromb. Vasc. Biol. 2006, 26:611-617.
37. Jackson-Lewis V., Jakowec M., Burke R.E., Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 1995, 4:257-269.
38. Jenner P. Oxidative stress and Parkinson's disease. Handb. Clin. Neurol. 2007, 83:507-520.
39. Kalia L.V., Lang A.E. Parkinson's disease. Lancet 2015, 386:896-912.
40. Kelly B., Tannahill G.M., Murphy M.P., O'Neill L.A. Metformin Inhibits the Production of Reactive Oxygen Species from NADH:Ubiquinone Oxidoreductase to Limit Induction of Interleukin-1β (IL-1β) and Boosts Interleukin-10 (IL-10) in Lipopolysaccharide (LPS)-activated Macrophages. J. Biol. Chem. 2015, 290:20348-20359.
41. Kieburtz K., Wunderle K.B. Parkinson's disease: evidence for environmental risk factors. Mov. Disord. 2013, 28:8-13.
42. Klegeris A., McGeer E.G., McGeer P.L. Therapeutic approaches to inflammation in neurodegenerative disease. Curr. Opin. Neurol. 2007, 20:351-357.
43. Klimek P., Kautzky-Willer A., Chmiel A., Schiller-Frühwirth I., Thurner S. Quantification of diabetes comorbidity risks across life using nation-wide big claims data. PLoS Comput. Biol. 2015, 11:e1004125.
44. Koepsell H., Lips K., Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res. 2007, 24:1227-1251.
45. Łabuzek K., Liber S., Gabryel B., Okopień B. Metformin has adenosine-monophosphate activated protein kinase (AMPK)-independent effects on LPS-stimulated rat primary microglial cultures. Pharmacol. Rep. 2010, 62:827-848.
46. Lawson L.J., Perry V.H., Dri P., Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990, 39:151-170.
47. Lesage S., Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 2009, 18:R48-R59.
48. Li L., Mamputu J.C., Wiernsperger N., Renier G. Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin. Diabetes 2005, 54:2227-2234.
49. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., Dawson V.L., Dawson T.M., Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 1999, 5:1403-1409.
50. Liou H.H., Hsu H.J., Tsai Y.F., Shih C.Y., Chang Y.C., Lin C.J. Interaction between nicotine and MPTP/MPP+ in rat brain endothelial cells. Life Sci. 2007, 81:664-672.
51. Ma T.C., Buescher J.L., Oatis B., Funk J.A., Nash A.J., Carrier R.L., Hoyt K.R. Metformin therapy in a transgenic mouse model of Huntington's disease. Neurosci. Lett. 2007, 411:98-103.
52. Mamputu J.C., Wiernsperger N.F., Renier G. Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab. 2003, 29(6):S71-S76.
53. Marchetti B., Abbracchio M.P. To be or not to be (inflamed)-is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?. Trends Pharmacol. Sci. 2005, 26:517-525.
54. Marchetti B., Serra P.A., Tirolo C., L'Episcopo F., Caniglia S., Gennuso F., Testa N., Miele E., Desole S., Barden N., Morale M.C. Glucocorticoid receptor-nitric oxide crosstalk and vulnerability to experimental parkinsonism: pivotal role for glia-neuron interactions. Brain Res. Brain Res. Rev. 2005, 48:302-321.
55. Marchetti B., Serra P.A., L'Episcopo F., Tirolo C., Caniglia S., Testa N., Cioni S., Gennuso F., Rocchitta G., Desole M.S., Mazzarino M.C., Miele E., Morale M.C. Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway. Ann. N. Y. Acad. Sci. 2005, 1057:296-318.
56. Matsuda W., Furuta T., Nakamura K.C., Hioki H., Fujiyama F., Arai R., Kaneko T. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J. Neurosci. 2009, 29:444-453.
57. McGeer P.L., McGeer E.G. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat. Disord. 2004, 10(Suppl. 1):S3-S7.
58. McGeer P.L., McGeer E.G. Glial reactions in Parkinson's disease. Mov. Disord. 2008, 23:474-483.
59. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
60. Miklossy J., Doudet D.D., Schwab C., Yu S., McGeer E.G., McGeer P.L. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp. Neurol. 2006, 197:275-283.
61. Nath N., Khan M., Paintlia M.K., Singh I., Hoda M.N., Giri S. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J. Immunol. 2009, 182:8005-8014.
62. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 1985, 36:2503-2508.
63. Olanow C.W., Schapira A.H., Agid Y. Neuroprotection for Parkinson's disease: prospects and promises. Ann. Neurol. 2003, 53(Suppl. 3):S1-S2.
64. Owen M.R., Doran E., Halestrap A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 2000, 348(Pt 3):607-614.
65. Patil S.P., Jain P.D., Ghumatkar P.J., Tambe R., Sathaye S. Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice. Neuroscience 2014, 277:747-754.
66. +, the monoamine oxidase catalyzed oxidation product of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J. Med. Chem. 1985, 28:1432-1436.
67. Postuma R.B., Gagnon J.F., Montplaisir J. Rapid eye movement sleep behavior disorder as a biomarker for neurodegeneration: the past 10 years. Sleep Med. 2013, 14:763-767.
68. Rogers J. The inflammatory response in Alzheimer's disease. J. Periodontol. 2008, 79:1535-1543.
69. Sag D., Carling D., Stout R.D., Suttles J. Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J. Immunol. 2008, 181:8633-8641.
70. Schernhammer E., Hansen J., Rugbjerg K., Wermuth L., Ritz B. Diabetes and the risk of developing Parkinson's disease in Denmark. Diabetes Care 2011, 34:1102-1108.
71. Stephenne X., Foretz M., Taleux N., van der Zon G.C., Sokal E., Hue L., Viollet B., Guigas B. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia 2011, 54:3101-3110.
72. Tanner C.M., Kamel F., Ross G.W., Hoppin J.A., Goldman S.M., Korell M., Marras C., Bhudhikanok G.S., Kasten M., Chade A.R., Comyns K., Richards M.B., Meng C., Priestley B., Fernandez H.H., Cambi F., Umbach D.M., Blair A., Sandler D.P., Langston J.W. Rotenone, paraquat, and Parkinson's disease. Environ. Health Perspect. 2011, 119:866-872.
73. Tansey M.G., McCoy M.K., Frank-Cannon T.C. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp. Neurol. 2007, 208:1-25.
74. Tatton N.A., Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 1997, 77:1037-1048.
75. Towler M.C., Hardie D.G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ. Res. 2007, 100:328-341.
76. Venero J.L., Santiago M., Machado A., Cano J. Determination of monoamine oxidase in rat's substantia nigra during postnatal development. Life Sci. 1989, 45:1277-1283.
77. Wong J.C., Hazrati L.N. Parkinson's disease, parkinsonism, and traumatic brain injury. Crit. Rev. Clin. Lab. Sci. 2013, 50:103-106.
78. Wu K.C., Lu Y.H., Peng Y.H., Tsai T.F., Kao Y.H., Yang H.T., Lin C.J. Decreased expression of organic cation transporters, Oct1 and Oct2, in brain microvessels and its implication to MPTP-induced dopaminergic toxicity in aged mice. J. Cereb. Blood Flow Metab. 2015, 35:37-47.
79. Xu Q., Park Y., Huang X., Hollenbeck A., Blair A., Schatzkin A., Chen H. Diabetes and risk of Parkinson's disease. Diabetes Care 2011, 34:910-915.